DNLI Denali Therapeutics Inc

Price (delayed)

$54.49

Market cap

$6.6B

P/E Ratio

87.89

Dividend/share

N/A

EPS

$0.62

Enterprise value

$6.24B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio has soared by 110% year-on-year and by 26% since the previous quarter
Denali Therapeutics's debt has decreased by 6% YoY
The EPS has soared by 128% YoY but it has decreased by 4.6% from the previous quarter
The net income has soared by 127% year-on-year but it is down by 19% since the previous quarter

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
121.19M
Market cap
$6.6B
Enterprise value
$6.24B
Valuations
Price to earnings (P/E)
87.89
Price to book (P/B)
5.96
Price to sales (P/S)
19.37
EV/EBIT
106.03
EV/EBITDA
93.04
EV/Sales
18.34
Earnings
Revenue
$339.98M
EBIT
$58.82M
EBITDA
$67.03M
Free cash flow
$415.39M
Per share
EPS
$0.62
Free cash flow per share
$3.44
Book value per share
$9.14
Revenue per share
$2.81
TBVPS
$12.8
Balance sheet
Total assets
$1.55B
Total liabilities
$442.51M
Debt
$67.79M
Equity
$1.11B
Working capital
$1.38B
Liquidity
Debt to equity
0.06
Current ratio
26.22
Quick ratio
25.88
Net debt/EBITDA
-5.48
Margins
EBITDA margin
19.7%
Gross margin
100%
Net margin
17%
Operating margin
15.1%
Efficiency
Return on assets
4.8%
Return on equity
6.4%
Return on invested capital
6.9%
Return on capital employed
3.9%
Return on sales
17.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
5.66%
1 week
-2.03%
1 month
4.27%
1 year
118.22%
YTD
-34.95%
QTD
-4.57%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$339.98M
Gross profit
$339.98M
Operating income
$51.47M
Net income
$57.86M
Gross margin
100%
Net margin
17%
The net income has soared by 127% year-on-year but it is down by 19% since the previous quarter
DNLI's operating income has surged by 122% year-on-year but it is down by 18% since the previous quarter
DNLI's operating margin has surged by 102% year-on-year but it is down by 19% since the previous quarter
Denali Therapeutics's net margin has soared by 102% YoY but it has decreased by 20% from the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
87.89
P/B
5.96
P/S
19.37
EV/EBIT
106.03
EV/EBITDA
93.04
EV/Sales
18.34
The EPS has soared by 128% YoY but it has decreased by 4.6% from the previous quarter
Denali Therapeutics's equity has surged by 103% YoY but it has decreased by 3.9% QoQ
DNLI's price to book (P/B) is 2.3% less than its last 4 quarters average of 6.1
The stock's price to sales (P/S) is 74% less than its last 4 quarters average of 75.9

Efficiency

How efficient is Denali Therapeutics business performance
The return on invested capital has surged by 117% year-on-year but it has declined by 32% since the previous quarter
The return on equity has surged by 114% year-on-year but it has declined by 30% since the previous quarter
The return on assets has surged by 114% year-on-year but it has declined by 32% since the previous quarter
The ROS has soared by 102% YoY but it has decreased by 19% from the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
DNLI's total liabilities has surged by 194% year-on-year but it is down by 2.5% since the previous quarter
The company's total assets has surged by 122% YoY but it fell by 3.5% QoQ
Denali Therapeutics's debt is 94% less than its equity
Denali Therapeutics's equity has surged by 103% YoY but it has decreased by 3.9% QoQ
DNLI's debt to equity has dropped by 54% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.